Dalbavancin

Mackie Research has upgraded CARDIOME PHARMA CORP (NASDAQ: CRME) to Speculative Buy from Hold on its recent licensing of Xydalba (Dalbavancin) from Allergan plc Ordinary Shares (NYSE: AGN) for $13 million up front. The Potential Power Of Dalbavancin Cardiome will also pay undisclosed "additional...